🫀 Oral semaglutide slows kidney decline in T2D, but no clear reduction in major kidney events
🔥 Main in 3 points
- Oral semaglutide did not significantly lower prespecified kidney composite outcomes in T2D patients with ASCVD/CKD (HR: 0.91; 95% CI 0.80–1.05; P=0.19), but slowed annual eGFR decline by 0.4 mL/min/1.73m² vs placebo (P<0.0001).
- Benefits consistent in CKD subgroups (eGFR <60) and across baseline characteristics; no excess of serious adverse events.
- Renal benefit present despite most participants having preserved eGFR at baseline.
🧪 Context
Double-blind RCT (SOUL trial), N=9,650 with T2D and ASCVD and/or CKD, 47.5 months follow-up, compared oral semaglutide vs placebo. Primary renal outcome: ≥50% eGFR decrease, eGFR <15, dialysis, or kidney/CV death.
📍 Practical significance
Oral semaglutide modestly slows kidney functional decline, but clinicians should not expect robust reduction in major renal events for T2D/CKD patients; use for kidney protection should be individualized alongside SGLT2i and other optimizers.
🔗 Source — PubMed | Full text - Diabetes Care
🛡️ No increased overall cancer risk with semaglutide or tirzepatide in major meta-analysis
🧪 What was studied
Randomized placebo-controlled trials (n=48) with >94,000 participants; GLP-1RAs for T2D and obesity; systematically assessed incidence of a wide range of obesity-related and endocrine cancers.
📈 Key results
No significant increase in risk for thyroid (OR 1.37, 95% CI 0.82–2.31), pancreatic, breast, kidney, or most other cancers in pooled analysis. Findings consistent for semaglutide and tirzepatide. Most evidence moderate certainty; studies not designed for cancer endpoints and median follow-up was relatively short.
📍 What this changes in practice
Clinicians can continue prescribing semaglutide and related GLP-1RAs without added cancer surveillance beyond usual care. Counsel on limitations—long-term cancer risk remains unclear; extra caution in patients with personal or family history of thyroid or endocrine tumors.
🔗 Source — PubMed | Annals of Internal Medicine
⚠️ Rare safety signal: Semaglutide-associated rhabdomyolysis
🧪 Context
Case report of a 36-year-old obese man developing severe rhabdomyolysis (CK 16,202 U/L, transaminase elevation, dark urine, leg pain), 6 days after semaglutide dose was increased from 1.7mg to 2.4mg weekly.
📊 Numbers
No other etiologies found; time course implicates dose escalation as precipitant.
📍 Actions
Monitor patients for severe muscle symptoms after rapid or high-dose titration, especially those with underlying comorbidities, high BMI, or on interacting drugs. Prompt CK and liver enzyme testing if myalgias or dark urine occur. Patient education on symptom reporting is key.
🔗 Source — PubMed | Full text - Clinical Kidney Journal
🧾 Semaglutide for obesity and MASH: Practical updates
✅ Do
- Use semaglutide for patients with obesity and moderate/advanced MASH: real-world evidence shows pronounced reductions in ALT (-19.4 U/L, 36%) and AST (-10.9 U/L, 29%) at 6 months, with significant weight and HbA1c improvement.
- Assess baseline liver enzymes and monitor changes alongside body weight and cardiometabolic risk factors.
⚠️ With caution
- Patients with advanced fibrosis/cirrhosis were less represented in new data—extrapolate with care.
- Gastrointestinal adverse events may limit adherence.
🚫 Avoid
- Use in patients with decompensated liver disease pending further data.
🔗 Source — PubMed | Current Medical Research and Opinion
👥 Real-world evidence: Sustained, trial-level weight loss with semaglutide up to 24 months
🧪 What was studied
Retrospective cohort of U.S. patients (n=2,592; 630 with full data) with obesity or overweight and at least one obesity-related condition, receiving semaglutide at 1.7mg or 2.4mg weekly, followed via EHR for 24 months.
📈 Key results
Mean weight loss at 24 months was -17.9 kg (-16.6%); BMI dropped -6.0 kg/m². Cardiometabolic risk factors (A1C, BP, cholesterol, triglycerides) significantly improved. Benefits observed in a routine care setting, not just trial conditions.
📍 What this changes in practice
Telehealth or standard clinics can achieve similar long-term efficacy and safety to pivotal trials for patients maintaining semaglutide, supporting broader adoption for chronic weight management.
🔗 Source — PubMed | Current Medical Research and Opinion
🏥 Semaglutide perioperatively: No increase in anesthesia-related complications for joint arthroplasty
❓ Practice question
Does ongoing semaglutide use before total joint arthroplasty (TJA) increase perioperative aspiration or anesthesia-related complications?
✅ Study answer
In a retrospective series of 83 TJA patients (76% on semaglutide), there were no documented cases of intraoperative aspiration. Only one patient (in dose-escalation phase) required gastric decompression. Adverse events and reoperation rates were not attributable to GLP-1RA therapy.
📍 How to apply
Current evidence supports continuing semaglutide perioperatively for TJA unless other risk factors are present. Individualize interruption if gastroparesis or nausea is problematic, especially during rapid up-titration.
🔗 Source — PubMed | European Journal of Orthopaedic Surgery & Traumatology
|
